Trial Profile
Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Lacnotuzumab (Primary) ; Spartalizumab (Primary)
- Indications Gastric cancer
- Focus Biomarker; Pharmacodynamics
- 08 Apr 2019 Status changed from not yet recruiting to recruiting.
- 10 Oct 2018 New trial record